FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a compound of structural formula I
which can be used for protecting cardiomyocytes or for preventing or treating a disease or a disorder related to cardiomyocyte apoptosis. In formula I A represents =S, -SR4 or =O, X represents F, Cl, Br or I, R1 represents phenyl, R2 and R3 are connected to form morpholine, and R4 represents C1-C6-alkyl.
EFFECT: invention refers to using the compound for producing the therapeutic agent for protecting cardiomyocytes or for preventing or treating a disease or a disorder related to cardiomyocyte apoptosis, and to the method for producing the above compounds.
8 cl, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW COMPOUNDS OF PYRROLOPYRIMIDINE AS INHIBITORS OF PROTEIN KINASES | 2013 |
|
RU2645672C2 |
| NOVEL PHARMACEUTICAL USE OF THIENO[3,2-D]PYRIMIDIN-4-ONE COMPOUNDS | 2019 |
|
RU2768828C1 |
| PHARMACEUTICAL APPLICATION OF HEXAHYDRO-DIBENZO[A,G]QUINOLIZINE COMPOUND | 2014 |
|
RU2704257C2 |
| PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | 2014 |
|
RU2677653C2 |
| ENPP1 INHIBITORS AND METHODS OF MODULATING THE IMMUNE RESPONSE | 2018 |
|
RU2800798C2 |
| COMPOUND FOR TREATING CANCER | 2014 |
|
RU2708247C2 |
| N1-(4-(5-(CYCLOPROPYLMETHYL)-1-METHYL-1H-PYRAZOLE-4-YL)PYRIDINE-2-YL)CYCLOHEXANE-1,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF CK1 AND/OR IRAK1 FOR THE TREATMENT OF CANCER | 2018 |
|
RU2761457C2 |
| HETEROCYCLIC AMIDE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PREPARATION AND USE THEREOF | 2020 |
|
RU2823875C1 |
| PHARMACEUTICAL COMPOSITION FOR INHIBITING NEURONAL APOPTOSIS OR NEURODEGENERATION | 2011 |
|
RU2586772C2 |
| BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS FOR USE THEREOF | 2015 |
|
RU2707280C2 |
